Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 9/20 | 0.48 |
| ▸ | TYR | P14679 | 2/20 | 0.36 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19837992 | 0.94 | ERN1 (0.50) | ERN1TYRTRIM24TRIM33CDK1 | |
| SCHEMBL31117267 | 0.94 | ERN1 (0.50) | ERN1TYRTRIM24TRIM33CDK1 | |
| SCHEMBL3404206 | 0.84 | ERN1 (0.52) | ERN1TYRTRIM24TRIM33 | |
| SCHEMBL29616071 | 0.83 | ERN1 (0.44) | ERN1TRIM24TRIM33 | |
| SCHEMBL206013 | 0.83 | ERN1 (0.44) | ERN1TRIM24TRIM33 | |
| SCHEMBL17807916 | 0.82 | ERN1 (0.56) | ERN1TYRTRIM24TRIM33CDK1 | |
| SCHEMBL29655114 | 0.80 | ERN1 (0.43) | ERN1TRIM24TRIM33 | |
| SCHEMBL933374 | 0.80 | ERN1 (0.43) | ERN1TRIM24TRIM33 | |
| SCHEMBL1860423 | 0.80 | ERN1 (0.54) | ERN1TYRTRIM24TRIM33CDK1 | |
| SCHEMBL30064066 | 0.80 | ERN1 (0.54) | ERN1TYRTRIM24TRIM33CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382312-A1 | BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | BORAH INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12466803-B2 | BCKDK inhibitors and/or degraders | PFIZER INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-12415771-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2025-09-16 | — | — | US | disclosed |
| US-12404286-B2 | Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof | BORAH, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| WO-2025049746-A1 | COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-114008012-B | Compounds for the treatment of neuromuscular disorders | NMD制药股份公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-4486390-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | Terremoto Biosciences, Inc (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240409609-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2024-12-12 | — | — | US | disclosed |
| US-20240352045-A1 | BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2024-10-24 | — | — | US | disclosed |
| US-20080177095-A1 | FUROCHROMAN DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| EP-1930396-A1 | Furochroman derivatives | MERCK PATENT GmbH (DE) | 2008-06-11 | — | — | EP | disclosed |
| EP-1194429-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2005-03-30 | — | — | EP | disclosed |
| US-6642222-B2 | Useful in hyperpolarizing cell membranes, opening potassium channels, relaxing smooth muscle cells, and inhibiting bladder contractions | ABBOTT LABORATORIES | 2003-11-04 | — | — | US | disclosed |
| US-6593335-B1 | Disease than can be ameliorated with a potassium channel opener in a host mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound of claim 1; said disease is epilepsy, Raynaud's | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |
| US-20030055035-A1 | Pyrano piperidino and thiopyrano compounds and methods of use | ABBOTT LABORATORIES | 2003-03-20 | — | — | US | disclosed |
| EP-1278747-A1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | Abbott Laboratories (US) | 2003-01-29 | — | — | EP | disclosed |
| EP-1194429-A1 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-10 | — | — | EP | disclosed |
| WO-2001083484-A1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2001-11-08 | — | — | WO | disclosed |
| WO-2000078768-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466803-B2 | BCKDK inhibitors and/or degraders | BCKDK, KHK, PDK4 | ERN1 829/4885TYR 4446/4885TRIM24 2425/4885 |
| US-20030055035-A1 | Pyrano piperidino and thiopyrano compounds and methods of use | KCNJ3, KCNJ6, KCNJ5 | ERN1 2698/4885TYR 4268/4885TRIM24 4074/4885 |
| US-20080177095-A1 | FUROCHROMAN DERIVATIVES | CFD, LMAN1, UROD | ERN1 2843/4885TYR 113/4885TRIM24 4389/4885 |
| US-20250382312-A1 | BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | JAK3, JAK1, JAK2 | ERN1 1139/4885TYR 209/4885TRIM24 1451/4885 |
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT1S1, AKT2 | ERN1 761/4885TYR 3676/4885TRIM24 1915/4885 |
| US-20240352045-A1 | BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | JAK3, JAK1, JAK2 | ERN1 1139/4885TYR 209/4885TRIM24 1451/4885 |
| US-20240409609-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF | EGFR, ERBB2, ERBB3 | ERN1 1399/4885TYR 2633/4885TRIM24 1331/4885 |
| US-12415771-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, SMN1; SMN2 | ERN1 2210/4885TYR 4363/4885TRIM24 919/4885 |
| US-12404286-B2 | Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof | JAK3, JAK1, JAK2 | ERN1 1139/4885TYR 209/4885TRIM24 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.